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Abstract
Background: In developing countries like Malawi, further investigation is rare after patients with chronic cough
test negative for tuberculosis. Chronic airways disease has presentations that overlap with tuberculosis. However,
chronic airways disease is often unrecognised due to a lack of diagnostic services. Within developing countries,
referral systems at primary health care level are weak and patients turn to unskilled informal health providers to
seek health care. Delayed diagnosis and treatment of these diseases facilitates increased severity and tuberculosis
transmission.
The World Health Organisation developed the Practical Approach to Lung Health strategy which has been shown
to improve the management of both tuberculosis and chronic airways disease. The guidelines address the need
for integrated guidelines for tuberculosis and chronic airways disease. Engaging with informal health providers has
been shown to be effective in improving health services uptake. However, it is not known whether engaging
community informal health providers would have a positive impact in the implementation of the Practical
Approach to Lung Health strategy. We will use a cluster randomised controlled trial to determine the effect of
using the two interventions to improve case detection and treatment of patients with tuberculosis and chronic
airways disease.
Methods: A three-arm cluster randomised trial design will be used. A primary health centre catchment population
will form a cluster, which will be randomly allocated to one of the arms. The first arm personnel will receive the
Practical Approach to Lung Health strategy intervention. In addition to this strategy, the second arm personnel will
receive training of informal health providers. The third arm is the control. The effect of interventions will be
evaluated by community surveys. Data regarding the diagnosis and management of chronic cough will be
gathered from primary health centres.
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Discussion: This trial seeks to determine the effect of Informal Health Provider and Practical Approach to Lung
Health interventions on the detection and management of chronic airways disease and tuberculosis at primary care
level in Malawi.
Trial registration: The unique identification number for the registry is PACTR201411000910192 – 21 November
2014
Keywords: Tuberculosis, Chronic airways disease, Non-communicable disease, Practical Approach to Lung Health
Background
Among non-communicable diseases (NCDs), respiratory
diseases represent a major burden of disease, in particular
chronic airways disease (CAD). CAD includes asthma,
chronic obstructive pulmonary disease (COPD) and
bronchiectasis. Risk factors for these conditions include
tobacco-smoking, indoor air pollution from biomass fuels
and lower respiratory tract infections.
Chronic or persistent coughing is a frequent clinical
presenting feature of both CAD and tuberculosis (TB).
Chronic cough is a distressing symptom and a common
reason for people to seek health services [1, 2]. Findings
from studies conducted in Malawi show that patients
presenting with cough exert a huge burden on out-
patient department (OPD) services [3], and yet there are
many challenges to providing effective care for patients
with respiratory symptoms in the OPD [4].
Chronic airways diseases
COPD is characterised by airflow limitation that is not fully
reversible but nonetheless treatable. The World Health Or-
ganisation (WHO) estimates that 65 million people have
moderate to severe COPD with 5 % of all (3 million) global
deaths being attributed to COPD [5]. About 90 % of these
COPD deaths occur in low-income and middle-income
countries. At the other end of the spectrum, asthma, a
chronic inflammatory disorder of the airways, is charac-
terised by episodes of reversible breathing problems (that
may be life-threatening) due to airway narrowing and
obstruction. These episodes are characterised by coughing,
wheezing, chest tightness and shortness of breath. The
frequency and severity of these episodes can have a marked
impact on the livelihoods and the well-being of those
affected [6]. Bronchiectasis is a severe, chronic infection of
the lung associated with permanent abnormal dilatation of
bronchi [7]. As a result mucus clearance is impaired, lead-
ing to accumulation of secretions, bacterial overgrowth and
recurrent infections.
Regular therapy of CAD with the rational use of inhaled
corticosteroids and bronchodilators can reduce the fre-
quency and severity of exacerbations. To date, inhaled cor-
ticosteroids and bronchodilators have not been consistently
available for use anywhere in Malawi’s health system, and
particularly not at primary care level. Because it is difficult
to diagnose CAD without appropriate equipment, unneces-
sary prescriptions of antibiotics are made for treatment.
Where available, inhalers are not used effectively because
the patients lack adequate education in their proper use.
Some patients are treated empirically for TB (sometimes
repeatedly) despite negative sputum smears because of a
lack of tools and guidelines for further screening for CAD.
Tuberculosis
TB is the world’s leading infectious cause of death in adults;
approximately 1.4 million deaths out of the 8 million an-
nual TB cases occur per year. TB predominantly affects the
respiratory system and chronic or persistent coughing is a
cardinal symptom. The Stop TB strategy relies heavily on
identifying and treating TB cases from among the large
group of patients who seek health care because of persistent
coughing. However, TB case detection remains a challenge
in most countries [8] and especially across sub-Saharan
Africa (SSA). Therefore, adult individuals with chronic re-
spiratory symptoms are potential TB cases and pose a rela-
tively high risk of onward transmission of TB. The WHO
estimates that Malawi is detecting only 50 % [9] of infec-
tious TB cases, which is below the global target of 70 % [9].
The relationship between non-communicable chronic re-
spiratory disease and TB
In developing countries with a high prevalence of TB, only
between 10 and 20 % of patients presenting in primary
care with persistent coughing will actually have TB. The
majority of the remaining 80 to 90 % of patients will be
suffering from a wide range of non-communicable chronic
respiratory diseases including CAD. A proportion of pa-
tients who have TB will also have underlying non-
communicable chronic respiratory disease. It is now in-
creasingly recognised that chronic respiratory diseases and
TB share risk factors including smoking and low socioeco-
nomic status. It is also recognised that a proportion of
patients who have not been treated effectively for TB will
develop chronic respiratory diseases, such as bronchiec-
tasis and fibrosis, as a result of the tissue destruction and
subsequent scarring [10].
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The impact of chronic airways disease and TB on
disability and quality of life
Severe CAD and TB exert disabling effects that reduce
quality of life and livelihood opportunities for the affected
individuals [11]. It is not known, however, what propor-
tion of patients with COPD are so severely affected as to
fulfil international criteria for disability, measured by level
and type of activity limitation [12]. People with disabilities
face particular challenges in accessing social and health
services and have higher risks of disease, including TB in-
fection [13]. These challenges, which include stigma and
discrimination, may cause patients with disabilities to fail
to access health services, remain in a morbid state, and
eventually be caught in a damaging cycle of disability, pov-
erty and ill-health.
The need for integrating approaches to CAD and TB case
detection and treatment
Despite the relationship between CAD and TB, health
systems in most developing countries have mainly focused
on the detection and cure of infectious diseases including
TB. There has been less emphasis on the diagnosis and
life-long management of CAD. As a result, patients with
chronic cough who do not end up with a TB diagnosis are
often frustrated because they are not given a diagnosis,
education about their condition or treatment. Given the
relationship between TB and CAD, integrated manage-
ment could reduce the proportion of patients with chronic
cough without a diagnosis, reduce costs and reduce mul-
tiple visits to health facilities for diagnosis.
For this reason, within the Stop TB strategy framework,
WHO and the International Union Against Tuberculosis
and Lung Disease (IUATLD) developed the Practical Ap-
proach to Lung Health (PAL) strategy. PAL is a patient-
centred approach to the diagnosis and treatment of com-
mon respiratory illnesses in health care settings other than
health centres at primary health care level. Specifically, the
PAL strategy aims to improve the quality of respiratory
disease management by promoting a symptom-based and
integrated approach to diagnosis and treatment. The aim
is to ensure standardised service delivery by the imple-
mentation of standardised clinical and diagnostic guide-
lines. The PAL strategy focuses on TB, pneumonia,
asthma and COPD.
In Syria and Jordan, where the PAL strategy has been
adopted, they have seen improvements in referrals, spu-
tum smear examinations, and a reduction in the pre-
scription of antibiotics for CAD, thereby markedly
reducing management costs [14, 15]. In Jordan, Abu
Rumman et al. found that the PAL approach decreased
the number of drugs prescribed per patient by 12.2 %
but increased the prescription of inhalers by 155 % [15].
Similarly, in Syria, Me’emary et al. showed a 14.8 % de-
crease in the number of drugs prescribed per patient
and a decrease of 27.4 % in the proportion of patients
who received antibiotic prescriptions [14].
Despite evidence for efficacy, the PAL strategy has not
been universally adopted in most developing countries,
including Malawi. This may be a result of poor accept-
ance and lack of political will by the national health
authorities, or due to concerns regarding the feasibility
of strategy implementation at primary health care facil-
ities which are managed by low-level and middle-level
health care workers.
The PAL strategy was designed for use in district hos-
pitals. However, there is some evidence that the ap-
proach can be implemented at primary health care levels
[13]. The studies in Syria and Jordan, as stipulated
above, used qualified medical doctors to implement the
PAL strategy. However, it is not clear whether it would
be feasible to implement the PAL strategy in primary
health care facilities staffed by low-level or middle-level
health cadres such as clinical officers, medical assistants
and nurses. Nonetheless, similarly adapted PAL ap-
proaches Practical Approach to Lung Health in South
Africa (PALSA) and Practical Approach to Lung Health
in Malawi (PALM) have been implemented in South
Africa [16, 17] and Malawi [18], respectively, using low
level cadres. However, these studies were primarily inter-
ested in assessing the impact of outreach training on the
recruitment and retention of staff.
In addition to the feasibility challenges of implement-
ing the PAL strategy in developing countries, access to
health services in general, and in particular CAD and TB
services, remains a challenge. These challenges are due
to both, health system and patient barriers [19]. Health
system barriers include inadequately qualified health
staff with insufficient training and a lack of equipment
and treatments.
Optimal utilisation of the available services is further
restricted by patient barriers such as poverty [20],
stigma, disability [21], low awareness levels for CAD and
TB as well as geographical barriers. These barriers
encourage patients to seek care from informal health
providers such as traditional healers and grocery shop
owners [22]. These informal health providers, in general,
lack the knowledge and skills needed to provide appro-
priate health care information, treatment and referrals to
health care centres. As a result, poor people accessing
care from informal health providers often experience de-
lays in treatment, waste time and resources, and worse
still, experience poor health outcomes [23].
In view of these patient barriers, strengthening
community-based structures could not only improve a
community’s knowledge on CAD and TB but also ser-
vice utilisation. Engagement of informal health providers
in delivery of health interventions to promote service
access is well documented. In Kenya, storekeepers have
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been used to recognise and treat uncomplicated malaria
in children and to refer to health services when needed
[6, 7]. In South Africa, storekeepers provided successful
supervision of TB treatment – directly observed treat-
ment (DOT) [24, 25]. A previous study in Malawi, con-
ducted by the REACH Trust, demonstrated that
storekeepers could promote TB case-finding [26] and
further work by the REACH Trust demonstrated that
informal providers can be engaged in the provision of in-
tegrated TB and HIV services at the community level.
We found that these interventions led to improvements
in HIV-testing by 61 %, anti-retroviral therapy (ART)
access rates by 34 % and diagnostic uptake rates for pre-
sumptive TB cases by 15 % (manuscript in preparation).
Aim
The proposed trial aims to determine the effect of In-
formal Health Provider and Practical Approach to
Lung Health interventions on the detection and man-
agement of CAD and TB at primary care level in
Malawi.
Methods - trial design
A cluster level randomised controlled open trial with
three arms.
Trial sites
The trial sites will be in the districts of Dowa and
Ntchisi, in the central region of Malawi. A total of 27
primary health centres in the districts will be involved
in the trial. Each cluster will include a primary health
centre together with the surrounding catchment area.
To reduce contamination between clusters there will
be a 3-km buffer zone between each cluster. The
health facilities have been selected based upon their
size according to the number of health workers and
type of service offered. Those with in-patient services
have been excluded. There are 11 such health centres
in Ntchisi and 16 in Dowa district. Private not-for-
profit health facilities, which run under the Christian
Health Association of Malawi (CHAM), have been
included.
Selection criteria
Inclusion criteria for health facilities
1. Health facilities that offer out-patient services only
2. Run by low-level and middle-level health care
workers
Exclusion criteria
1. Health facilities offering in-patient services
2. Health facilities run by qualified medical doctors
Sources of recruitment
A community engagement exercise will be carried out to
seek community leader and local community support for
the trial. Participants selected for participation in the
baseline or follow up household surveys will be visited at
their homes and invited to participate.
Inclusion criteria for individual participants
All consenting individuals aged 15 and above will be eligible
to participate.
Exclusion criteria
1. Individuals below the age of 15 years.
According to TB control guidelines those below the
age of 15 years are less likely to expectorate sputa
for TB screening and they fall into a paediatric
group
2) Refusal to participate in the survey will also be an
exclusion criterion
3) Visiting members of the household
Allocation of interventions
Each cluster (health centre with the surrounding catch-
ment area) that has agreed to participate will be ran-
domly allocated to one of the three trial arms using a
computer-generated randomisation schedule with strati-
fication by size of cluster. This randomisation will be
performed by the trial statistician using dummy codes ‘A’
‘B’ and ‘C’ to represent intervention and control groups;
to ensure the statistician remains blinded, the identity
(allocation) of ‘A’ ‘B’ and ‘C’ will be determined by a per-
son independent of the study.
The interventions
Intervention arm 1 – Health centres implementing the
PAL intervention. No informal provider intervention.
Intervention arm 2 – Health centres implementing the
PAL intervention. Informal provider intervention.
Control arm – No intervention at health centre or
informal provider level. Routine standard care will be
provided.
Detail of the health centre-based PAL intervention in arms 1
and 2
The intervention at health centres will involve training
medical assistants and nurses on the PAL guide-lines
and use of spirometry for the diagnosis and assessment
of airflow limitation in patients presenting with chronic
cough. The trial will test the feasibility of implementing
PAL strategy and integrating TB screening and CAD at
the lowest level in the health system in Malawi. Lessons
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learnt are expected to influence policy and practice
countrywide.
Other indicators to measure impact of the trial will
include: occurrence and frequency of hospitalisations
due to exacerbations, time lapse between symptom
development and diagnosis. For TB patients, changes
in this diagnostic delay may be a proxy indicator of
health outcomes.
Training of health care providers will include:
1. Training of health centre staff on identifying and
managing TB and CADs from amongst those with
chronic cough.
2. Introducing the use of standardised registers for
patients presenting with chronic cough.
3. Introducing the syndromic approach and spirometry
for the diagnosis of airway diseases and TB among
patients with chronic cough.
4. Introduction and uninterrupted use of inhalers
(bronchodilators and corticosteroids) for patients
diagnosed with asthma.
5. Introduction and uninterrupted availability and use
of inhalers (bronchodilators) for patients diagnosed
with COPD.
The aim is that after training the medical assistants
and nurses in the intervention health centres will com-
petently carry out the following tasks:
1. Screen and identify COPD, bronchiectasis, TB and
asthma cases among patients presenting with
chronic cough to primary health care facilities.
2. Use appropriate screening and diagnostic tools and
specimens for the diagnosis of COPD,
bronchiectasis, TB and asthma.
3. Make appropriate referral of patients to, and receive
corresponding feedback from, secondary referral
health facilities in the districts.
4. Perform accurate recording and reporting of all
cases using tools for the PAL guidelines.
5. Provide key health messages about TB and CAD as
part of the routine health talks.
Detail of the informal health provider intervention in arm 2
The intervention directed at the community level in
intervention arm 2 will aim to build the capacity of
informal health providers (IHPs) to recognise, counsel
and refer potential TB and CAD patients in their
communities.
Mapping of IHPs in the clusters allocated to inter-
vention arm 2 will be done after randomisation. A
qualitative study going on in the neighbouring district
of Kasungu to explore how the communities under-
stand IHPs by type and role will inform the trial to
use the right definitions of informal health providers.
During the mapping exercise distribution of IHPs will
be determined prior to selection and training them in
order to be within the buffer zones.
This intervention will include:
1. Training of informal health providers in the
recognition, counselling and referral of patients with
chronic/persistent cough to the primary health
facility.
2. Training of informal health providers in prevention
of COPD and including smoking cessation.
3. Training informal health providers to support
patients with airway diseases so that they adhere to
both drug and non-drug therapies and compliance
to appointments.
4. Training of local health centre staff and health
surveillance assistants to give supervisory support to
informal health provider activities.
5. Establishment of referral mechanisms between the
community and the health system.
Thus, once trained informal care providers will be re-
quired to routinely carry out one or more of the following
tasks according to their capacity and prevailing circum-
stances as part of their daily activities:
1. Recognise selected presentations of chronic cough
and potential TB cases among eligible persons,
including persons with disability, in their
communities.
2. Communicate effectively with patients and members
of the public to i) encourage and support positive
health-seeking behaviour, ii) provide key health mes-
sages about COPD, bronchiectasis, TB and asthma
among chronic respiratory diseases and iii) provide
reliable information on the available services for these
diseases at the primary health care facilities in the
area.
3. Advise on appropriate screening and diagnostic
specimens for TB diagnosis (e.g. sputum).
4. Recommend and provide appropriate information
about COPD, bronchiectasis, TB and asthma to
encourage positive health care-seeking behaviour
and adherence to specific disease risk reduction
measures.
5. Refer to, and receive feedback from local public
health services at primary health care level, for all
identified cases with CADs and suspected TB
cases.
6. Competently record and report on all cases referred
to primary health care and activities done in the
community.
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Outcome assessments
Primary outcome measures
1. Proportion of the population with a chronic cough
who have a diagnosis of TB or airway disease(s)
recorded in their health passports.
This has been selected as the primary outcome since
this is the most clinically relevant outcome effect meas-
urable immediately downstream of the intervention.
This intervention is measurable at the community level,
thus requiring a community-based survey to collect out-
come data.
Secondary outcome measures
1. Proportion of the population with a chronic cough
on salbutamol/corticosteroid inhaler indicated in
their health passports.
2. Proportion of the population with a chronic cough
with a diagnosis of TB or airway disease among
patients with chronic cough attending primary
health care recorded in patient registers at
intervention facilities.
3. Proportion of people with disabilities with a
diagnosis of TB or airway disease recorded in their
health passports in all arms of the study.
In order that diagnoses of CAD, including asthma and
TB are made with a high level of accuracy, appropriate
merit-based training of spirometry technicians will be
done by a competent (PATS/ERS/ATS) certified trainer.
Spirometry technicians will further undergo refresher
training during the trial. Diagnosis of TB will be based on
the routine practice of TB microscopy and chest X-rays
(CXRs). In some instances the Gene Expert test will be
performed according to an available standard algorithm.
We will consider to undertake a systematic investigation
of the accuracy of diagnoses made in a subset of patients
by checking results, clinical notes in patient health pass-
ports, and CXR’s, along with a thorough clinical review.
Limitations for diagnosis include lack of sputum cul-
ture for TB diagnosis and computed tomography (CT)
scan for conditions like bronchiectasis. Unfortunately
sputum culture and CT scans are beyond the funding
scope of the study.
Case report forms
Electronic case report forms (CRFs) programmed onto
smartphones using Open Data Kit (ODK) will be used to
make the large number of CRFs manageable and provide
real-time data entry, internal validity and consistency
checks. CRFs will be treated as confidential documents
and held and backed up on two secure servers. Data will
be anonymised prior to analysis.
Potential risks to the safety of the trial participants
Trial participants will be recruited from populations liv-
ing in poor conditions in Malawi who live with relatively
high day-to-day risks. The interventions are particularly
low-risk and targeted at improving access to medical
care for those at need. Overall we anticipate that partici-
pation in the trial will reduce risks to participants.
Adverse event reporting
An adverse event (AE) is any unfavourable and unin-
tended sign, symptom, syndrome or illness that develops
or worsens during the period of observation in the study.
A Serious Adverse Event (SAE) is an AE following the
intervention that results in a) death, b) a life-threatening
AE, c) hospitalisation or prolongation of an existing
hospitalisation, d) disability or incapacity, e) congenital
anomaly in the offspring of a participant.
The interventions we will be using in this trial are par-
ticularly low-risk interventions that offer potential safety
benefits (e.g. improved access to care). Nevertheless, we
will collect data about AEs. Data about AEs that are not
serious will be collected with the population-based
survey at the end of the trial. Participating health centres
will be asked to report SAEs in relation to the interven-
tions immediately to the trial coordinating centre. The
trial coordinating centre will collect details about the
SAE using a pro-forma in accordance with a specific
standard operating procedure (SOP). This information
will then be passed immediately to Hastings Banda who
will conduct a causality assessment (not related/improb-
able, possible, probable, definite), assess seriousness and
expectedness, take any appropriate medical action and
inform the College of Medicine Research Ethics Com-
mittee (COMREC) and the Liverpool School of Tropical
Medicine Research Ethics Committee (LSTM REC) of
any events deemed related to the trial intervention
within 7 days of knowledge of the event. All other SAEs
will be reported as part of an annual report to COMREC
and LSTM REC. All SAEs that relate to the interven-
tions will be followed to resolution.
Sample size and sampling approach
The primary objective of this study is to measure the
impact of the interventions on the proportion of chronic
cough patients with a diagnosis of CAD or TB in their
health passport. The preliminary sample size consider-
ations set out below are based solely on expert opinion;
these assumptions and estimations for the follow-up
impact study will be revisited in light of the data col-
lected during the baseline survey.
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Baseline survey
Data on CAD is not routinely collected in the study dis-
tricts, so to inform the final sample size estimation a base-
line survey will be conducted, the purpose of which will
be to estimate the proportion of individuals over the age
of 15 years in each cluster with (a) evidence of chronic
cough-/- wheeze, and (b) a diagnosis in their health
passport.
For this baseline survey, it will be assumed that for the
study population:
(i) the mean household size in the study area will be
4.6
(ii) the proportion of individuals over the age of
15 years will be 0.52 (52 %)
(iii)so the average number of individuals per household
over the age of 15 years will be 4.6 × 0.52 = 2.4
As described in detail in table 1, a 3-stage sampling
procedure will be used:
 Stage 1: a random sample of 27 clusters (health
centres with surrounding catchment areas) will be
selected and 9 of these randomly allocated to each
study arm
 Stage 2: 30 villages will be randomly selected from
each of these 27 clusters based on sampling
probabilities proportional to village population again
using Google Earth Pro (Google Inc., Mountain
View, CA, USA) to identify villages and to estimate
their sizes (total 810 villages: 270 per study arm)
 Stage 3: a simple random sampling procedure will
be applied to select 7 households from each selected
village (total 5,670 households: 1,890 per study arm)
All eligible participants in each selected household will be
interviewed, giving a total sample of 5,670 × 2.4 = 13,608
individuals (4,536 per study arm); 10 % of these individuals
(1,360 in total: 453 per study arm) will be expected to show
evidence of chronic cough-/-wheeze.
The precision figures quoted below for this baseline
survey use the approximate formula for a 95 % confidence
interval ‘1.96 × standard error of prevalence estimate’. In
the actual analysis, exact binomial confidence intervals will
be computed, but these are asymmetric so unsuitable for
presenting a simple indication of the precision levels that
will be achieved.
Assuming a prevalence of 10 %, a sample of 4,536
individuals will provide an estimate of the true preva-
lence of chronic wheeze-/-cough in each individual
study arm with a precision of ±0.87 %. Ignoring clus-
tering effects, the 13,608 individuals in all 3 study
arms combined will provide a precision of ±0.50 %;
adding a design effect size adjustment of 2 to allow
for clustering effects, the combined sample will have
a precision of ±0.71.
Assuming that 5 % of individuals who demonstrate
symptoms of chronic cough-/-wheeze will have a diag-
nosis of CAD or TB in their health passport, a sample of
453 individuals will provide an estimate of the true
health burden prevalence in each individual study arm
with a precision of ±2.00. Ignoring clustering effects, the
1360 individuals in all 3 study arms combined will pro-
vide a precision of ±1.17 %; adding a design effect size
adjustment of 2 to allow for clustering effects, the com-
bined sample will have a precision of ±1.64 %.
(N.B. The effects of clustering within households,
within villages and within health centre catchment areas
will all be fully adjusted for in the statistical analysis
using multi-level modelling methods). A summary of
sampling steps and estimated numbers for the baseline
survey is shown in Additional file 1: BANDA Additional
file 1.pdf, 235 K.
Estimation of impact of PAL alone and PAL + IHP
interventions versus control
The calculations presented below use an alpha level of
2.5 % rather than the conventional 5 % to allow for 2
primary comparisons (PAL + IHP versus control and
PAL alone versus control).
Exactly the same 3-stage sampling procedure will used
as for the baseline survey, except that now 14 house-
holds will be selected from each village (total 11,340
households: 3,780 per study arm). As before, all eligible
participants in each selected household will be inter-
viewed, giving a total sample of 11,340 × 2.4 = 27,216
individuals (9,072 per study arm); 10 % of these individ-
uals (2,721 in total: 907 per study arm) will be expected
to show evidence of chronic cough-/wheeze.
The available evidence indicates that approximately
5 % of symptomatic individuals in the control group
post-intervention will have a diagnosis in their health
passport. The PAL + IHP intervention will be considered
clinically important if it increases the proportion of
symptomatic individuals with a registered diagnosis from
5 to 20 %.
With 9 clusters per group and 907 symptomatic indi-
viduals per study arm (100 per cluster), this study will
have 80 % power to detect a clinically important differ-
ence between the PAL + IHP and control groups pro-
vided the BCV (between-clusters CV (coefficient of
variation)) does not exceed 62.9 %, and will have 90 %
power if the BCV does not exceed 54 %.
BCV measures the extent to which the proportion of
symptomatic individuals with a registered diagnosis varies
between the clusters, and expresses this as a percentage of
the average proportion of symptomatic individuals with a
registered diagnosis across all clusters combined. In most
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community interventions, BCV is usually less than or
equal 25 % [27] so, even at worst, this element of the study
will have over 90 % power.
The PAL alone intervention will be considered clinic-
ally important if it increases the proportion of symptom-
atic individuals with a registered diagnosis from 5 to
10 %. With 9 clusters per study arm and 100 symptom-
atic individuals per cluster, the study will have 80 %
power to detect a clinically important difference between
the PAL alone and control groups provided the BCV
does not exceed 24.1 %, and 90 % power if the BCV does
not exceed 13.7 % (so the actual power of this element
of the study is expected to be at, or close to, 80 %). A
summary of sampling steps and estimated numbers for
the post-intervention survey is shown in Additional file
2: BANDA Additional file 2.pdf,233 K.
Data collection and management
The baseline survey will be conducted prior to random-
isation and prior to intervention implementation. The
follow-up survey will be conducted 1 year after interven-
tion implementation. Data will also be gathered from
health centres 1 year after the interventions have been
implemented.
Measures will be taken to ensure quality and accuracy
of information, which will be collected and reported;
these will include: firstly, thorough training of health
workers – the training content will include proper re-
cording of diagnoses based on knowledge of presenting
symptoms and signs of each condition and the differen-
tial diagnoses. In addition health care workers will also
be taught about spirometry results so that they acquire
understanding to help with them in interpreting spirom-
etry results to make accurate diagnosis. Secondly, the
trial clinical supervisor will routinely undertake monitor-
ing of practice in the intervention health facilities to
ensure that standards are being followed regarding prac-
tice, recording and reporting. Patient health passports,
PAL registers at facilities and spirometry records will be
assessed during the visits.
The data collected from health registers as digital im-
ages will be scanned into an electronic database using
Teleform software (Cardiff Software, Sunnyvale, CA,
USA) or, if this proves to be technically difficult; the
scanned images will be double-entered by trained data
entry clerks into an Microsoft Access for windows or
Epi-Info 6.04 database, a free software developed by the
Center for Disease Control of Atlanta in the United
States of America.
All other quantitative data will be collected on pre-
prepared and validated pro-formas by trained researchers.
All forms completed on any given day will be checked
visually at the end of the day and any data queries identi-
fied (including missing entries) will be checked with
theresearchers. The data will then be double-entered onto
a pre-prepared Access or Epi-Info computer database, and
the original pro-formas will be stored in locked filing cabi-
nets in a secure area within the research centre. This will
serve as a data security measure and also to protect confi-
dentiality. The computer server holding the Epi-Info data-
bases will be backed-up daily to a second server held in an
area physically separate from the primary server; a sec-
ondary back-up will also be made onto a portable disk-
drive, which will be held in a locked cabinet for safety and
security.
All principal investigators will be given access to the
final cleaned data sets. Data will be anonymised to main-
tain confidentiality.
Statistical analysis plan
The characteristics of the individuals recruited into
study surveys will be summarised using means, median
or proportions, as appropriate. All summary statistics
will be accompanied by their standard deviations or
95 % confidence intervals, again as appropriate. Missing
or invalid observations detected during this analysis will
be referred back to the field-based researchers for
clarification.
Effect sizes for the study outcome measures will be
summarised using incidence rate ratios with their 95 %
confidence intervals. Negative binomial and/or Poisson
regression methods will be used to adjust these effect
sizes for potential influencing/confounding factors; the
influence of these factors on the effect size incidence
rate ratio estimate will be reported for each factor indi-
vidually and then for all factors combined. Multiple
imputation methods will be used to accommodate any
missing observations that could not be clarified by the
field researchers.
The analyses will be conducted under the supervision
and advice of Dr. Brian Faragher, a senior lecturer in
Medical Statistics at Liverpool School of Tropical Medicine.
Interim analyses and stopping rules
Data collection for this trial will be conducted at base-
line and at the end of the trial. There will, therefore, be
no opportunity for an interim analysis to inform stop-
ping the trial early. We consider this to be acceptable
given the low-risk nature of the trial.
Ethical aspects
Ethics committee approvals
The protocol has been reviewed and fully approved by the
COMREC in Malawi. Ethical approval has also been ob-
tained from the Liverpool School of Tropical Medicine.
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Protocol amendments
Any significant amendment to the protocol will require
agreement of the TSC and approval of both COMREC
and LSTM REC. Information regarding protocol amend-
ments will be disseminated to relevant parties including
investigators, field workers, health centres, IHPs and
participants as appropriate.
Informed consent form and information sheets
Prior to conducting each and every interview, an informa-
tion sheet will be used to fully inform the potential partici-
pant. Prior to completing any interviews or collecting any
study-related data, a consent form will be completed and
signed. This process with be adapted for any potential par-
ticipants who are unable to read such that the information
sheet will be read out and the consent form completed
with assistance from the field team. A mark witnessed by
someone independent to the study will be accepted where
participants are unable to sign.
Informed consent will be obtained by the following
team from the REACH Trust:
1. Hastings TR Banda; Principal Investigator, Dip Clin
Med (Malawi), MCommH (Liv), UK
2. Grace Bongololo Mbera; Social Scientist, BA, MA
(Mw)
3. Kassim Kwalamasa, Social Scientist, BA (Mw)
4. Martina Mchenga, Health Economist, BA, MA
(Mw)
5. Blessings Chisunkha, Data Coordinator, BSc (Mw)
6. Brian Ngwira, Clinical Supervisor, Dip Clin Med
(Mw), BSc Med (Mental Health) (Mw).
Consideration of potential risks to participating health
centres and their catchment populations
The interventions being tested in this cluster level rando-
mised trial are applied at a community or health centre
level. At a community level, this is a signposting system
and does not involve any treatments. At the health centre
level we will be implementing an advanced care package
that only contains components that would be considered
standard good practice. At intervention health centres,
each individual will, therefore, be managed with standard
care and the additional diagnostic capabilities and treat-
ments. Training will be given on the management of CAD
and TB including managing any side effects of inhalers.
As neither of the interventions are medications we have
not included specific criteria for the modification or dis-
continuation of interventions. Individual treatments that
have been initiated at the health centres can be discontin-
ued by the patients at any time. There are no restrictions
on the concomitant care that participants may receive
during the trial.
If patients receive a diagnosis of CAD they may be
given either salbutamol and/or corticosteroid inhalers,
these have minimal side effects. Salbutamol inhalers may
lead to a transient increase in heart rate, decreased
plasma potassium concentration and decreased diastolic
pressure. Side effects of corticosteroid inhalers include
oesophageal candidiasis, dysphonia, wheezing and cough.
Prolonged use of inhaled corticosteroids may increase the
risk of developing TB in patients who are being treated for
COPD [27]. Although the drugs used in this study are
routinely used in health facilities in Malawi, the study will
closely monitor and document any reported side effects
and where possible the frequency of intake of these drugs
may be reduced. Health facility staff will manage the side
effects and refer to the district hospital if appropriate.
Furthermore, adequate training in the use of inhalers and
corticosteroids and side effects recognition will be given
to minimise the occurrence of these side effects. Training
on use of spirometers for diagnosing airflow limitation will
also be given. This training will be facilitated by a chest
specialist (Dr. Kevin Mortimer) who is part of this study.
Trial management
Trial protocol review and registration
The protocol was submitted for review and has been
registered with The Pan African Clinical Trial Registry
(www.pactr.org) database and will be published in an
open access format. Registration data set details are in
Additional file 3: BANDA pdf, 231 K.
Arrangements for day-to-day management
A full time on-site qualified and experienced clinical of-
ficer (Hastings Banda) has been appointed and will have
responsibility for day-to-day management issues, super-
vision of field workers and data manager, protocol
compliance, security of the randomisation process, re-
cruitment, data management, problem identification and
resolution, distribution and maintenance of trial mate-
rials, budget control and production of annual progress
reports. Hastings Banda will be supported by the
REACH Trust, a trial management group and a super-
visory group (Moffat Nyirenda, Kevin Mortimer, Bertie
Squire, and Rachael Thomson).
The Trial Management Group (TMG) led by the clin-
ical officer will be established to manage the trial on a
day-to-day basis. The TMG will meet at least monthly
and will monitor trial conduct, progress, adherence to
the protocol and SOPs, CRF completion, accuracy and
completeness of data collection, data validity and, where
necessary, act to safeguard trial participants and quality
standards. The TMG will receive logistic and infrastruc-
tural clinical trials support from the Liverpool School of
Tropical Medicine Tropical Clinical Trials Unit.
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Research governance arrangements
Trial oversight committees will be established including
the TMG and the trial steering committee (TSC). LSTM
as trial sponsor will perform an initial start-up and then
annual Good Clinical Practice (GCP) compliance visits
to ensure and document complete compliance. All trial
staff and investigators will protect the rights of partici-
pants to privacy and informed consent. Internal quality
control monitoring will be conducted 3-monthly to en-
sure understanding of protocol and SOPs, protocol and
GCP compliance, conduct source document (health
passports) verification and confirm that all participating
households have given written informed consent. The
internal quality control monitoring will be conducted by
the investigators and the TSC. This process is independ-
ent of the trial sponsor. Participation in the trial involves
low risk interventions and procedures that are not
expected to increase the risk of SAE above the normal
baseline for poor people in Malawi. All SAEs will be
reported to the TSC and via onward reports to COM-
REC and LSTM REC. Trial participants and trial staff
will be covered by LSTM indemnity and insurance. The
principal investigators will maintain all records and doc-
uments regarding the conduct of the study and retain
these for at least 7 years or for longer if required. The
Trial Master File and trial documents shall be finally
archived at secure archive facilities at LSTM or the
REACH Trust.
Data Monitoring Committee
As discussed by the TSC, a Data Monitoring Committee
is not considered necessary given the low risk nature of
the trial interventions and given the lack of interim data
analysis opportunities. Any data monitoring that may be
required will be overseen by the TSC.
Trial Steering Committee
A TSC has been established to provide overall supervi-
sion of the trial and is chaired by a member from among
independent members who are in majority. The TSC
meets face-to-face prior to trial initiation to agree the
trial protocol and terms of reference and will convene at
least annually henceforth through conference calls and
one further face-to-face meeting if needed. The principal
investigator in association with the chair will take
responsibility for calling and organising TSC meetings.
Timeline
The project is planned to run from January 2014 to
December 2016. Interventions are planned to be im-
plemented from March 2014 to February 2015. The
final results are expected in December 2016.
Publication and dissemination of results
The trial findings will be presented at international confer-
ences and published in peer-reviewed journals in an open
access format. Results will be communicated to the par-
ticipating health centres. The district health management
team and the district executive committee will be briefed
regarding the trial results.
Discussion
The trial will undertake two cross-sectional household
surveys: one at the beginning of the trial, prior to ran-
domisation of clusters, and the second after the inter-
ventions have been in place for a year. Although the
intervention is health centre-based to improve quality of
service the primary outcome measure will be assessed in
the communities. Trial data, therefore, will have several
sources including cross-sectional household surveys,
clinic registers, and patient health passports. Monitoring
and supervision tools will be developed to support the
completeness and accuracy of these data. A subset of
patients will be selected to assess quality and accuracy of
diagnosis and patient management.
Trial status
This trial has approval from COMREC as well as from
LSTM REC. All health centres have been selected. The
trial has been registered with the Pan African Clinical
Trials Registry.
Additional files
Additional file 1: Baseline sampling steps and summary of
estimates. (DOCX 18 kb)
Additional file 2: Post-intervention sampling steps and summary
estimates. (DOCX 19 kb)
Additional file 3: Trial registration details. (DOCX 21 kb)
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